Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

1994 • 5,204 citations

The Dendritic Cell System and its Role in Immunogenicity

1991 • 4,733 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

1988 • 2,121 citations

Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

1996 • 1,854 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Pancreatic Carcinoma

1992 • 1,175 citations

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

1999 • 339 citations

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.

1995 • 324 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 308 citations

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo

1996 • 308 citations

Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

1995 • 264 citations

Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

1996 • 256 citations

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

1995 • 213 citations

Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.

1991 • 210 citations

Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins.

1991 • 208 citations

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12VAL) peptide vaccination of a patient, recognize 12VAL-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1997 • 163 citations

A Phase I Vaccine Trial with Peptides Reflecting ras Oncogene Mutations of Solid Tumors

1999 • 117 citations

Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study

1996 • 112 citations

Generation of Stable CD4+and CD8+T Cell Lines from Patients Immunized withrasOncogene-Derived Peptides Reflecting Codon 12 Mutations

1997 • 88 citations

p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4⁺ and CD8⁺ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp)

1994 • 85 citations

Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201

1995 • 84 citations

UTERINE ADENOMATA IN THE RABBIT

1941 • 68 citations

Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gin → Leu61)

1992 • 67 citations

CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.

1995 • 63 citations

Overlapping epitopes encompassing a point mutation (12 Gly → Arg) in p21 ras can be recognized by HLA‐DR, ‐DP and ‐DQ restricted T cells

1993 • 60 citations

CD8+T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (GLY13?ASP), are cytotoxic towards a carcinoma cell line harbouring the same mutation

1995 • 60 citations

Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater--the prognostic factors influencing the long-term results. A prospective multicentre study.

1993 • 49 citations

K-ras mutations and HLA-DR expression in large bowel adenomas

1996 • 37 citations

Cited By (0)

Loading...